INTRODUCTION
============

African trypanosomes are extracellular parasites, which circulate in the bloodstream and tissue fluids of their mammalian hosts and are transmitted by tsetse flies in sub-Saharan Africa. They are responsible for the human disease sleeping sickness, or human African trypanosomiasis (HAT), caused by two subspecies of *Trypanosoma brucei*; *T. b. gambiense* causes the chronic form of the disease in West and Central Africa, and is responsible for the vast majority of disease cases ([@B12]), whilst *T. b. rhodesiense* causes the acute form in East Africa. Both are widely believed to be fatal unless adequate treatment is provided. The number of cases has recently decreased due to increased surveillance, treatment of cases, and targeting of the insect vector.

Both forms of HAT comprise two stages: stage one where the parasites spread through the haemo-lymphatic system from the site of the tsetse bite and stage two where the parasites cross into the cerebro-spinal fluid (CSF) via the blood-CSF and blood-brain barrier and establish an infection in the central nervous system (CNS; [@B45]). If left untreated, the disease caused by either species leads to coma and death ([@B12]).

Most trypanosomes have to survive within two hosts, mammalian and insect, necessitating adaption to differing nutritional environments, and remodelling of their surface coat ([@B32]); and must also live within two specialized environments in their mammalian host. In the bloodstream and lymphatic system the parasites evade both the acquired and innate immune systems, predominantly by antigenic variation, changing the variant surface glycoprotein (VSG) expressed on their surface to avoid antibody-mediated responses ([@B32]). During the second stage of infection, in the CNS, they are more protected from the immune system, and may exist as a reservoir, able to reinfect the bloodstream, for example after treatment with drugs which do not penetrate into the CSF ([@B45]).

The closely related, but human serum sensitive species *T. congolense*, *T. vivax*, and *T. brucei brucei* cause the veterinary disease animal African trypanosomiasis (AAT) or nagana, a severe, often fatal, wasting disease, principally affecting cattle, but also importantly sheep and goats, and which renders livestock farming across the tsetse belt of Africa extremely challenging ([@B63]). *T. vivax* can also be transmitted mechanically by bloodsucking insects, and such transmission has been found in Central and South America ([@B35]), and in non-tsetse infested regions of Ethiopia ([@B17]; [@B30]). The disease Surra, a similar wasting disease to nagana, is caused by *T. evansi*, which has lost its maxicircle kinetoplast DNA and thus the procyclic stage of its lifecycle, and as such does pass through an insect vector, instead being mechanically transmitted between hosts by blood-feeding insects ([@B39]). It is the most widely distributed animal trypanosomiasis, being found in Asia, northern and northeastern Africa, Central America and South America, within a variety of host species, mainly causing disease in horses, camels, and water buffaloes, although it can also affect other equines, cattle, goats, sheep, elephants, cats, and dogs ([@B29]; [@B50]). A further trypanosomiasis of horses and donkeys, dourine, is caused by the related species, *T. equiperdum*, which also cannot pass through an insect vector, being instead, uniquely amongst trypanosomal diseases, transmitted though sexual contact ([@B39]). It causes a variety of genito-urinary symptoms, along with anemia and emaciation, leading to nervous symptoms ([@B50]).

TREATMENT OF HAT
================

There are currently five treatment options for HAT: pentamidine, suramin, melarsoprol, eflornithine monotherapy, and nifurtimox--eflornithine combination therapy (NECT); which drug is used is mostly dependent on disease stage and the infecting subspecies, as well as on availability of the medication. Pentamidine is used for early stage HAT caused by *T. b. gambiense*; whilst early stage *T. b. rhodesiense* is treated with suramin ([@B12]). Both were introduced in the early 20th century, with pentamidine discovered in 1937 and suramin in 1916 ([@B27]; [@B63]).

For patients with second-stage disease, melarsoprol has been widely used as the first line drug for decades, despite the fact that the drug causes fatal reactive encephalopathy in 2--5% of patients depending on the infective species ([@B12]), possibly due to rapid lysis of large amounts of parasites in the brain. Over the last 15 years, increasing rates of melarsoprol treatment failures have also been reported, with rates between 20 and 39% being seen in some foci of infections in Uganda, Republic of South Sudan, Angola, and the Democratic Republic of Congo (DRC; [@B37]; [@B13]; [@B46]; [@B62]; [@B56]; [@B47]).

Eflornithine was introduced in 1990, and has been freely available since 2001 ([@B60]), but despite the increasing failures of melarsoprol treatment, it did not replace melarsoprol as a first line treatment due to a number of significant problems: it is only effective against *T. b. gambiense* parasites, it is expensive and requires logistically difficult administration procedures, requiring four daily intravenous infusions for 14 days ([@B60]). Partly due to the ease of inducing eflornithine resistance in the laboratory ([@B68]) and anecdotal reports of eflornithine treatment failures, clinical trials were conducted to assess the efficacy of combinations of eflornithine, melarsoprol and the oral drug nifurtimox, which is commonly used to treat Chagas disease ([@B60]). Ultimately, after phase III trials, the combination of nifurtimox and eflornithine (or NECT) was found to have the same safety and efficacy as eflornithine treatment alone, but to have the significant advantages of reducing both the dose and treatment time necessary for cure and of being less likely to induce resistance than eflornithine mono-therapy ([@B53]). Thus, the World Health Organization ([@B71]) recommended that NECT should be used for treatment of second-stage *T. b. gambiense* sleeping sickness, and melarsoprol use has rapidly declined. Although between 2001 and 2006 the number of *T. gambiense* cases treated with eflornithine only increased from 3 to 12%, by 2009 the proportion treated was 66% and after NECT was added to the WHO essential medicines list in 2009 the proportion treated with this combination increased to 88% in 2010 ([@B60]). Melarsoprol does of course remain the only treatment available for late-stage *T. b. rhodesiense* HAT, making study of the mechanisms of resistance crucial.

TREATMENT OF AAT
================

Currently three drugs are most commonly used for AAT: the diamidine compound dimiazene aceturate (DA), and the phenanthridines isometamidium chloride (ISM) and ethidium bromide; although ISM is principally used prophylactically ([@B28]). The effective treatment of livestock remains hugely important for farmers within the tsetse belt of Africa, with an estimated 46 million head of cattle at risk of trypanosomiasis ([@B64]). The disease is controlled by both vector control and chemotherapy, with an estimated 35 million doses of trypanocides administered annually ([@B33]), although the effectiveness of all trypanocides is threatened by drug resistance ([@B34]; [@B28]).

DRUG RESISTANCE AND TRANSPORTERS
================================

TBAT1/P2
--------

Melarsoprol/pentamidine cross resistance (MPXR) is a well-known phenomenon in HAT, first described by [@B57]; and although the cause was never completely resolved, it has long been clear that it was linked to reduced drug accumulation ([@B19]; [@B31]; [@B20]). The first drug transporter identified in trypanosomes was the P2 adenosine/adenine transporter, which was originally connected to melarsoprol uptake ([@B16]) and subsequently to diamidine transport ([@B7]; [@B15], [@B14]; [@B26]; [@B23]). The P2 gene was the first nucleoside transporter to be cloned from trypanosomes, with the gene designated as *TbAT1* ([@B40]). Although the evidence for diamidine and arsenical transport by TbAT1/P2 is unquestionable, it has become equally clear that TbAT1/P2 mediates only a proportion of the uptake of both diamidines and arsenicals ([@B21]; [@B10]). The proportion of uptake varies in particular for different diamidines, as the deletion of *TbAT1* led to a high level of resistance to the veterinary diamidine DA ([@B43]) and the newer clinical candidates furamidine and CPD0801 ([@B70]), but only to a minor loss of sensitivity for melaminophenyl arsenicals and for pentamidine ([@B43]; [@B11]). Thus, *T. brucei* is sensitive to these diamidines only because it expresses this unique adenosine/adenine transporter -- a very rare example of a transporter with virtually equal affinity and transport efficiency for a nucleoside and its nucleobase ([@B24]). The *TbAT1* allele may be the random result of extensive gene duplication, as the *T. brucei* genome contains at least 15 genes of the equlibrative nucleoside transporter (ENT) family ([@B24]). Interestingly, the related parasite *T. congolense*, which is a major pathogen of livestock in sub-Saharan Africa, also has a major amplification of the ENT family (up to 19 members), but phylogenetically most of these cluster as nucleobase transporters rather than nucleoside transporters (P1-cluster) or nucleoside/nucleobase transporters (P2 cluster; [@B49]). As such, *T. congolense* does not have a counterpart of *TbAT1* ([@B49]) and is much less sensitive to diminazene (Munday and De Koning, in preparation), although this is the main drug for the treatment of *T. congolense* infection.

The mode by which TbAT1 recognizes substrates as different as diminazene, adenine, melarsoprol, adenosine and pentamidine, while displaying total selectivity for aminopurines (adenosine/adenine) over oxopurines (inosine, hypoxanthine, guanosine, guanine) has been investigated in detail. From an initial analysis of substrate selectivity, using purine analogs, it was clear that the main recognition site was the so-called 'amidine' motif =N-CH(R)-NH2 consisting of N1 and the 6-position amine group of the purine ring ([@B14]; [@B25]). Substrate recognition was modelled in great detail using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices analysis (CoMSIA), which produced a predictive pharmacophore model using a very diverse dataset of binding energies for 112 compounds ([@B18]).

The functional loss of TbAT1 has been linked to drug resistance in *T. brucei* species, starting with the seminal paper by [@B16] showing that trypanosomes resistant to melaminophenyl arsenicals had lost 'an unusual adenosine transporter.' This transporter was cloned by [@B40] and a 'resistance allele' with several single nucleotide polymorphisms was linked to the failure to sensitize cells to the arsenicals. Similar mutations were also detected in clinical isolates and linked to high levels of melarsoprol failure in Uganda ([@B42]). However, it has become clear that the model for melarsoprol resistance is more complicated ([@B22]; [@B4]), with loss of at least one additional transporter necessary for the high-resistance phenotype ([@B11]).

ADDITIONAL PENTAMIDINE/ARSENICAL TRANSPORTERS IN *T. brucei*
------------------------------------------------------------

Studies with \[^125^I\]-iodopentamidine showed that only half the pentamidine transport capacity of *T. brucei* is sensitive to inhibition by adenosine or adenine, and identified an additional low affinity pentamidine transporter, LAPT1 ([@B26]). A further high affinity pentamidine transport activity, HAPT1, was identified using \[^3^H\]-pentamidine of high specific activity, which allowed the very low substrate concentrations required to detect this transport activity ([@B21]). This established a model of three pentamidine transporters with *K*~m~ values of approximately 35 nM (HAPT1), 300 nM (P2), and 35 μM (LAPT1; [@B22]). HAPT1 was additionally found to be a transporter for the arsenical drugs, with the loss of both the TbAT1 and HAPT1 transporters simultaneously leading to high-level MPXR ([@B11]; [@B22]), and also to mediate a small proportion of diminazene uptake ([@B65]), although the latter is clinically insignificant. The very low flux of diminazene through HAPT1, relative to TbAT1, shows that this transporter is far more selective in the transport of diamidines. We have observed that, particularly, diamidines that lack a flexible linker chain between the benzamidine end groups tend to be poorly recognized and transported by HAPT1 ([@B70]), which helps explain the much higher activity of pentamidine than diminazene against *T. brucei* species.

EFLORNITHINE TRANSPORTER
------------------------

Transporters were similarly found to be crucial for sensitivity and resistance to another essential anti-trypanosomal drug, eflornithine. The *T. brucei* transporter of eflornithine, AAT6, was identified in 2010 via metabolomic analysis of eflornithine-resistant parasites, which indicated a low level of eflornithine in the resistant parasites, and the subsequent sequencing of the predicted *T. brucei* amino acid transporter genes, which found that the locus of TbAAT6 and several adjacent genes was lost in the resistant line. The identification of TbAAT6 as the transporter of eflornithine was confirmed using specific gene knockdown with RNA-interference (RNAi), which resulted in resistance to eflornithine. Moreover, the expression of TbAAT6 in an eflornithine-resistant line reversed the resistance phenotype ([@B68]). Two RNAi library screens also identified TbAAT6 as the transporter of eflornithine and the main determinant of resistance to the drug ([@B3]; [@B59]). TbAAT6 was subsequently confirmed to be a functional amino acid transporter, with its expression allowing growth of *Saccharomyces cerevisiae* mutants on neutral amino acids ([@B41]).

AQUAPORINS IN *T. brucei*
=========================

There are three aquaglyceroporins in the *T. brucei* genome, AQP1-3, which transport a number of traditional aquaglyceroporin substrates, including water, glycerol, urea, dihydroacetone ([@B67]), and ammonia ([@B72]), as well as the trivalent metalloids arsenite and antimonite ([@B66]). The relatively high number of AQPs expressed in *T. brucei* and other extracellular parasites has been hypothesized to be due to their need to survive in the extracellular environment, and/or to the differentiation between the different parasitic lifecycle stages necessary for survival in both mammalian and sandfly hosts, with the accompanying morphological and functional changes to their surface membranes ([@B61]). The three *T. brucei* aquaporins have differing localisations, with TbAQP1 located on the flagellar membrane, TbAQP3 on the plasma membrane ([@B8]) and TbAQP2 in the flagellar pocket in bloodstream form parasites and on the plasma membrane in procyclic-form parasites ([@B5]). Interestingly, TbAQP2 and TbAQP3 are not essential for *in vivo* replication, nor indeed for testse-mediated transmission, as *in vivo* drug pressure can lead to the loss of these genes (see below).

UNUSUAL PORE OF TbAQP2
======================

TbAQP2 contains non-standard motifs in key portions of the gene which are thought to determine the selectivity of the pore, whereas AQP3 has standard selectivity region amino acids. TbAQP2 is the only Major Intrinsic Protein (MIP) family member so far described that has NSA/NPS and IVLL motifs, whilst TbAQP3 and TbAQP1 both contain the classical NPA/NPA motifs present in most other family members ([@B5]), and a WGYR motif in the selectivity region common to 118 aquaglyceroporin-type pores ([@B4]). Particularly, the absence of the aromatic/arginine (ar/R) motif in AQP2 may lead to an increase in its ability to transport larger and charged molecules as has been found for mammalian aquaporin 1 ([@B9]; [@B38]; [@B55]).

LOSS OF TbAQP2 CAUSES MELARSOPROL-PENTAMIDINE CROSS RESISTANCE (MPXR)
=====================================================================

*T. brucei* aquaporins 2 and 3 were initially identified as being potentially important for MPXR by an RNAi library screen. The two genes are arranged on chromosome 10 in a tandem array and share 83% sequence identity ([@B1]). By expressing each gene separately in aqp2--aqp3 double null cells, it was shown that TbAQP2 was the determinant for pentamidine and arsenical sensitivity/resistance ([@B5]).

The open reading frame of *TbAQP2* was investigated in the well-characterized laboratory-selected strain B48, which has high levels of resistance to both pentamidine and melarsoprol, having had *TbAT1* deleted by homologous recombination and lost HAPT1 because of continuous passage in increasing concentrations of pentamidine ([@B11]). In this strain a *TbAQP2-3*~(569-841)~^[1](#fn01){ref-type="fn"}^ chimeric gene, inactive with respect to pentamidine sensitivity and transport, was found to have replaced *TbAQP2*; a 272-bp section toward the 3′ end of *TbAQP2* was replaced in-frame with the corresponding section of *TbAQP3* ([@B5]), see **Figures [1A,B](#F1){ref-type="fig"}**. This suggested that it was this latter section of the gene which is at least partially responsible for the drug-sensitivity profile of *TbAQP2*, and this section does include the second half of the likely selectivity region (NPS/IVLL is replaced with the classical regions of NPA/IGYR in the chimera). The chimeric gene was found to have assumed the location pattern of TbAQP3, being found across the whole plasma membrane ([@B48]).

![**Schematic of the documented AQP2 and AQP3 loci in lab-derived and field-isolated strains of *Trypansoma brucei*.** Brown lines = SNPs in chimeras compared to WT; yellow lines = position of NSA/NPS loci from *TbAQP2*; pink lines = position of NPA/NPA loci from *TbAQP3*. **(A)** Locus found in wildtype strains (*T. b. brucei* Lister 427, 247, and TREU927; *T. b. gambiense* 386, STIB 930, and DAL972; and *T. b. rhodesiense* STIB900 (minor differences in *TbAQP3* are not highlighted); **(B)** Locus with chimera *TbAQP2-3*~(569-841)~ from lab-derived pentamidine resistant strain B48 ([@B5]); **(C)** Locus of chimera *TbAQP2-3*~(376)~ from lab-derived melarsoprol resistant strain 247-Mr ([@B48]); **(D)** Locus in lab-derived melarsoprol resistant strains 386-Mr and STIB900-Mr; and lab-derived pentamidine resistant strain STIB900-PR ([@B48]), and in one *T. b. gambiense* K03048 allele ([@B36]); **(E)** Locus with chimera *TbAQP2-3*~(814)~ found in field isolates from Mbuji-Masi locus in DRC and the other K03048 allele ([@B36]; [@B54]); **(F)** Locus with chimera *TbAQP2-3*~(880)~ found in all *T. b. gambiense* field strains from Mbuji-Masi ([@B54]); **(G)** Locus with chimera *TbAQP2-3*~(678-880)~ found in two old Congolese *T. b. gambiense* field strains, MBA and KEMLO ([@B54]) and **(H)** Chimera *TbAQP2-3*~(617-658)~, without loss of *AQP3*, from four *T. b. gambiense* field strains isolated in Masi-Manimba ([@B54]).](fphar-06-00032-g001){#F1}

The aquaporins present in other lab-derived MPXR strains, produced by selection with the water-soluble derivative of melarsoprol, cymelarsan, have also been assessed. In the *T. b. gambiense* line 386-Mr, the *TbAQP2* gene was completely absent (**Figure [1D](#F1){ref-type="fig"}**); whilst in the *T. b. brucei* 247-Mr line a different chimera, *TbAQP2/3*~(364)~, had been produced via the loss of both wild-type *TbAQP2* and *TbAQP3* (**Figure [1C](#F1){ref-type="fig"}**) The 247-Mr chimera was in frame, comprised of the first 363 bp of *TbAQP2* and the last 576 bp of *TbAQP3*; thus the protein contains both of the NPA/NPA selectivity motifs of *TbAQP3*. In a further two MPXR strains, produced by *in vivo* selection of the *T. b. rhodesiense* strain STIB900 to grow in either pentamidine or melarsoprol, the *TbAQP2* genes were found to be absent altogether ([@B48]; **Figure [1D](#F1){ref-type="fig"}**).

RE-EXPRESSION OF *TbAQP2* REVERSES MPXR
=======================================

Re-expression of *TbAQP2* in B48 cells re-established the sensitivity of the parasites to pentamidine and cymelarsan and restored the missing HAPT1 activity; expression of *TbAQP2* in *Leishmania mexicana* promastigotes also introduced HAPT1 function, with kinetic parameters indistinguishable from those obtained in *T. brucei*, and greatly sensitized the parasites to pentamidine and cymelarsan. In contrast, expression of the chimeric *TbAQP2-3*~(569-841)~ gene from the B48 strain in *Tbaqp2* null parasites had no significant effect on the sensitivity of the parasites to pentamidine and cymelarsan, showing that *TbAQP2-3*~(569-841)~ is not a functional pentamidine/cymelarsan transporter ([@B48]), although it is as yet unclear whether it forms a functional aquaporin.

TbAQP2 IN FIELD ISOLATES
========================

The above studies established that *TbAQP2* encodes the HAPT1 transport activity, and that alterations in the *TbAQP2* locus were the main determinant of MPXR in lab-derived strains. However, it was vital to verify whether TbAQP2 defects also contribute to MPXR in field isolates; this has now been completed in two separate studies, using *T. gambiense* isolates which were found to have reduced melarsoprol sensitivity in *in vivo* tests ([@B36]; [@B54]). Firstly, the *TbAQP2-AQP3* locus was genotyped in a number of *T. gambiense* field isolates (both recent and historical; from patients who either relapsed or were cured after melarsoprol treatment). In the five recent isolates from the Mbuji-Masi focus in the DRC, which were isolated from patients who relapsed after melarsoprol treatment, a single in-frame, chimeric *TbAQP2-3*~(814)~ gene was found instead of the native tandem gene locus ([@B36]). The first 813 bp of the chimera were from *TbAQP2*, with the remaining 126 bp end of *TbAQP3*. In this chimera, the putative NSA/NPS selectivity region of TbAQP2 is retained, see **Figure [1E](#F1){ref-type="fig"}**. In an older isolate from South Sudan, K03048, heterozygosity in the locus was observed; one allele contained only *TbAQP3*, having lost *TbAQP2*, whilst the other allele was composed of a similar *TbAQP2-3*~(814)~ chimera to that found in the DRC strains (**Figures [1D,E](#F1){ref-type="fig"}**). This South Sudanese isolate was also from a patient who relapsed after melarsoprol treatment. The wildtype *TbAQP2* allele was found in a number of older strains, isolated from 1960 to 1995, which came from patients either successfully cured by melarsoprol treatment, or whose treatment outcome is unknown ([@B36]).

Further recent *T. b. gambiense* isolates from the Mbuji-Masi focus in the DRC have now been analyzed, including several pairs of isolates collected before and after treatment with melarsoprol ([@B54]). In 12 of these strains, the *TbAQP2-3*~(814)~ chimera was found one of these isolates had been previously sequenced by [@B36], which is a chimera containing only the last 43 amino acids of AQP3 (**Figure [1E](#F1){ref-type="fig"}**). By direct sequencing, a further *TbAQP2-3*~(880)~ chimera was found from the Mbuji-Masi strains; comprising of the first 879 bp of *TbAQP2,* with a SNP of T869C, followed by an in-frame switch to the last 60 bp of *TbAQP3* (**Figure [1F](#F1){ref-type="fig"}**). Thus these strains, despite being from patients both cured and relapsing after treatment with melarsoprol, seem all to contain the two heterozygous chimeric alleles, *TbAQP2-3*~(814)~ and *TbAQP2-3*~(880)~ ([@B54]). In two old isolates of *T. b. gambiense*, MBA and KEMLO ([@B52]), from the DRC, another chimera was found. The patient history of these strains is unknown, however, the strains have lost the native *TbAQP2* and *TbAQP3* genes, instead having a chimera consisting of the first 677 bp of *TbAQP2*, then the next 202 bp of *TbAQP3*, followed by the final 60 bp from *TbAQP2* (see **Figure [1G](#F1){ref-type="fig"}**). This *TbAQP2-3*~(678-880)~ chimera, similarly to that found in the lab strain B48 (described above), lacks the second half of the likely selectivity region, with the NPS/IVLL residues of *TbAQP2* replaced with the classical region, NPA/IGYR in the chimera ([@B54]).

A further four strains of *T. b. gambiense*, isolated in 2001 from the Masi-Manimba focus in the DRC, where high relapse rates after melarsoprol treatment have never been found, were also investigated. These four strains were isolated from patients cured of their trypanosomiasis by melarsoprol treatment and appear to be heterozygous, containing both a *TbAQP2* gene which contains 18 single nucleotide polymorphisms (SNPs) compared to that found in the wild-type *T. b. gambiense* strain STIB930, as well as a chimera of the first 616 bp of *TbAQP2* (with two SNPs), a 41 bp region of *TbAQP3* and the last 282 bp of *TbAQP2* ([@B54]; **Figure [1H](#F1){ref-type="fig"}**). This *TbAQP2-3*~(617-658)~ chimera from the Masi-Manimba focus retains the potential NSA/NPS selectivity region of TbAQP2, providing a potential explanation for the assumed sensitivity of these strains to melarsoprol treatment.

So far, it has not been investigated whether the various chimeras found in these *T. b. gambiense* field isolates are capable of transporting pentamidine or melarsoprol, and further expression studies are necessary. However, in all the lab-derived and field isolates with reduced sensitivity to, or relapse after treatment with, melarsoprol and/or pentamidine *TbAQP2* has been found to be altered in some way. In the isolates from some cured patients the wild-type *TbAQP2* was present, although with a number of SNPs, alongside a *TbAQP2-3* chimera, which retains the unusual selectivity region of *TbAQP2*. At least one of the chimeras, from the lab-derived resistant strain, has been shown to be incapable of transporting pentamidine; and thus TbAQP2 appears to be a determinant of the efficacy of pentamidine and melaminophenyl arsenicals.

SELECTIVITY FILTER
==================

The organization of the AQP2/AQP3 locus in the various strains so far investigated is shown in **Figure [1](#F1){ref-type="fig"}**. In many cases *TbAQP2* has been recombined into a chimeric gene that possesses most of the AQP3 selectivity filter. Thus, the potential of the selectivity regions to determine the MPXR has been investigated ([@B48]). Synthetic genes encoding either the B48 chimera *TbAQP2-3*~(569-841)~ or *TbAQP3* containing the selectivity region of *TbAQP2* were expressed in the *aqp2/aqp3* null line; only for the *TbAQP2-3*~(569-841)~ chimera (which already contains the first part of the selectivity motif, as part of the first 561 bp of *TbAQP2* in the chimeric protein), did introduction of the second *TbAQP2* selectivity region affect sensitivity to cymelarsan, reaching susceptibility to this drug halfway between the *aqp2/aqp3* null and the same line expressing WT TbAQP2, indicating that more residues in the first portion of *TbAQP2* are necessary than just the predicted selectivity region; this conclusion was underscored by the observation that the effect was only apparent for arsenical drug sensitivity and that pentamidine sensitivity was not affected by the change ([@B48]).

MODELLING OF TbAQP2
===================

The predicted binding modes of pentamidine and melarsoprol are shown in **Figures [2A,B](#F2){ref-type="fig"}**, respectively. The two guanidine groups of pentamidine are predicted to interact with main-chain carbonyl oxygen atoms of residues located near both the extracellular and cytoplasmic side of the protein channel (**Figure [2A](#F2){ref-type="fig"}**). Similarly to pentamidine, one of the melamine amino substituents of melarsoprol is predicted to interact with main-chain carbonyl oxygen atoms of residues located near the extracellular side, whilst the hydroxyl group of melarsoprol is predicted to interact with the amidic side-chain group of Asn130 (**Figure [2B](#F2){ref-type="fig"}**). The pore size of TbAQP2 is sufficiently large to accommodate either pentamidine or melarsoprol (**Figure [2C](#F2){ref-type="fig"}**), with both ligands able to assume distended conformations.

![**Predicted binding of pentamidine and melarsoprol in complex with a single TbAQP2 subunit (green). (A)** Binding of pentamidine (cyan carbon atoms). **(B)** Binding of melarsoprol (orange carbon atoms). Key polar interactions are shown for both **(A,B)**. **(C)** Top extracellular view of the overlay of the docked binding poses of pentamidine (cyan carbon atoms) and melarsoprol (orange carbon atoms). The protein was modeled using MODELLER 9.14 ([@B58]), using as a template the crystal structure of PfAQP (PDB code: 3c02) published by [@B51]. The sequence identity between TbAQP2 and the template was 33%. The images were created using PyMOL version 1.50.04 (Schrödinger). PyMOL was used to generate the biological units for the aquaglyceroporin from Plasmodium falciparum (generation of symmetry mates). Molecular docking was performed using FRED ([@B44]), using a multiconformer database generated using OMEGA. The docked poses were energy minimized using SZYBKI (version 1.7.0) allowing partial relaxation of the protein residues in the direct proximity to the ligand. FRED, OMEGA, and SZYBKI are software developed by OPENEYE (OpenEye Scientific Software: Santa Fe, NM, USA).](fphar-06-00032-g002){#F2}

The tetrameric structure of the protein models of TbAQP2, TbAQP3, and *TbAQP2-3*~(569-841)~ chimera are shown in **Figures [3A,C](#F3){ref-type="fig"}**, respectively. The key pore forming residues listed in **Table [1](#T1){ref-type="table"}** are also shown in **Figure [3](#F3){ref-type="fig"}** in space-filling models. The structural alignment of these protein models suggests that TbAQP3 and the TbAQP2-3~(569-841)~ chimera contain pore-forming residues which have bulkier side-chains than with TbAQP2. This could explain the lack of drug transport activity by TbAQP3 and TbAQP2-3~(569-841)~ chimera given the predicted smaller pore in these subunits in comparison with TbAQP2. AQP3, at least, is known to retain normal transport functions for the much smaller water and glycerol substrates ([@B8]), as well as for inorganic As(III) and Sb(III) ([@B66]). In particular, TbAQP3 contains three residues (Trp102, Tyr250, and Arg256) whose side-chains protrude into the pore of the channel. These residues align with residues with smaller side-chains in TbAQP2 (Ile110, Leu258 and Leu264, respectively; **Table [1](#T1){ref-type="table"}**; **Figures [3A--C](#F3){ref-type="fig"}**). Similarly, in the TbAQP2-3~(569-841)~ chimera, Tyr258 and Arg264 are likely to be responsible for the lack of transport, as the side-chains of these residues are also predicted to protrude into the pore channel. These predictions are currently under experimental investigation using site-directed mutagenesis.

![**Extracellular top view of the tetrameric structures. (A)** TbAQP2; the residues constituting the NSA, NPS, and IVLL motif are shown in space-filling models and the locations of Ile110, Leu258, and Leu 264 are indicated in one subunit. **(B)** TbAQP3; the residues constituting the two NPA and WGYR motif are shown in space-filling models and the locations of Trp102, Tyr250, and Arg256 are indicated in one subunit. **(C)** TbAQP2-3~(569-841)~; the residues constituting the NSA, NPS, and IGYR motif are shown in space-filling models and the locations of Ile110, Tyr258, and Arg264 are indicated in one subunit. The images were created using PyMOL version 1.50.04 (Schrödinger). The proteins were modeled using MODELLER 9.14 ([@B58]), using as a template the crystal structure of PfAQP (PDB code: 3c02; ([@B51])). The sequence identity between the target and the template was 33, 36, and 34% for TbAQP2, TbAQP3, and the TbAQP2-3~(569-841)~ chimera, respectively. The C-alpha atoms of chain A, B, C, and D of the tetramer template were restrained during homology modeling using MODELLER in order to reduce the number of interatomic distances that need to be calculated.](fphar-06-00032-g003){#F3}

###### 

Key pore-forming residue differences among TbAQP2, TbAQP3, and the TbAQP2-3~**(569**-**841)**~ chimera.

  TbAQP2   TbAQP3   TbAQP2-3~(569-841)~
  -------- -------- ---------------------
  Ile110   Trp102   Ile110
  Asn130   Asn122   Asn130
  Ser131   Pro123   Ser131
  Ala132   Ala124   Ala132
  Val249   Gly241   Gly249
  Leu258   Tyr250   Tyr258
  Asn261   Asn253   Asn261
  Pro262   Pro254   Pro262
  Ser263   Ala255   Ala263
  Leu264   Arg256   Arg264

CONCLUDING REMARKS
==================

All the drugs currently in use against trypanosomiasis were identified through *in vivo* disease models and/or phenotypic screens *in vitro*. To a large extent, these toxic chemicals, including diamidines, arsenicals, eflornithine, and even suramin ([@B27]; [@B1], [@B2]), act selectively on trypanosomes because of unique transport mechanisms, explaining the enormous differences in potency against the closely related *Leishmania* species. Just the expression of the single gene *TbAQP2* in *L. mexicana* promastigotes rendered these parasites 40-fold sensitive to pentamidine and \>1000-fold more sensitive to Cymelarsan ([@B48]). Conversely, the same transporters that make the current chemotherapy against sleeping sickness possible are the cause of drug resistance when their activities are lost.

Thus, the main reason for the sensitivity of trypanosomes to the drugs used against them is that they have unique transporters, and although these transporters are easily recognized as being from ubiquitous gene families, there is currently no way to predict their unusual substrate specificity and role from their primary sequences. The drug transporters so far identified still function efficiently as would be expected from their homologs in other species: i.e., as a purine transporter (P2/TbAT1), an aquaglyceroporin (TbAQP2), and as an amino acid transporter (TbAAT6). It is only because trypanosomal drug transport has been studied in the amount of detail that it has been, that the drug transport activities have been identified for these otherwise relatively unremarkable members of ubiquitous gene families. This leads to the important conclusion that any transporter may be a potential drug transporter and that there is no narrowly defined class of 'drug transporters,' nor any transporter families that can be excluded from that category.

As there are so many transporters in the *T. brucei* genome it is possible to do this the other way round, i.e., to try to generate a drug that will enter trypanosomes through a specific transporter ([@B6]; [@B69]). In such a scenario, given that loss of transporters has been demonstrated to give rise to resistance, it would be important to assess by how many transporters any new compounds are taken up; this could lead to minimisation of the risk of transporter-related resistance for new compounds, especially if the transporter, like any individual purine transporter, TbAQP2 or TbAAT6, are non-essential. In each case a single point mutation (such as the introduction of a STOP codon or frame shift) could be sufficient to induce a high level of drug resistance, apparently with no fitness cost.

The unusual aquaglyceroporin TbAQP2 was found to encode the high affinity pentamidine transporter (HAPT1), ([@B48]), and appears to be vitally important for sensitivity to pentamidine and melaminophenyl arsenicals ([@B5]; [@B36]). It may be possible to test for MPXR by assessing the presence of wild-type TbAQP2 alleles in clinical samples. However, this is unlikely to deliver a simple test as there is no single, easily confirmed mutation and the emerging data suggest that many different mutations or rearrangements can give rise to loss of AQP2 as a drug transporter ([@B36]; [@B48]; [@B54]), it would probably require sequencing of the complete AQP2-AQP3 locus to identify any changes and adjust drug treatment plans accordingly. Even then, we need to know more about the link between observed mutations to the drug transport activity of the gene product, which will require functional expression and analysis of all chimeras and mutants identified. Only if we can gain sufficient insights of all the structural determinants of drug tranport by TbAQP2 may we be able to base treatment decisions on *TbAQP2* sequnce analysis. The model presented here provides testable hypotheses for not just the structure of the aquaporin, but also the residues involved in binding of pentamidine and melarsoprol.
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As multiple different chimeric AQP2/3 chimeric genes are being reported in connection with (potential) drug resistance, it is important to have a nomenclature that unambiguously identifies each isolate. In brackets the first numbers indicate the first nucleotide that is unambiguously AQP3 sequence; the second number is the first nucleotide after that to be unambiguously AQP2 sequence. If there is no second number the sequence reads as AQP3 to the end.
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